Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grape bar study hopes to fight inflammation naturally

NCT ID NCT07395921

Disease control Sponsor: Center for Research and Innovation Viña Concha y Toro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether eating a grape pomace bar enriched with resveratrol can lower inflammation and improve heart-related health in 75 adults living in the community. Participants will eat the bar daily, and researchers will measure changes in blood markers of inflammation and antioxidant levels. The goal is to see if this simple food-based approach can help manage chronic low-grade inflammation, a risk factor for many diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Comunnity-dwelling persons. * Any ethnicity. * With willingness to consume the bar daily during the intervention period. Exclusion Criteria: * Allergy/intolerance to ingredients in the bar. * Pregnancy or breastfeeding. * Use of antioxidant/polymeroid supplements in the last 4 weeks. * Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer). * Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication). * Persons with metal prosthesis. * Persons undergoing or waiting for metabolic bariatric surgery. * Persons with scheduled digestive surgery within the next 8 weeks * Persons in recent treatments for hypertension (less than 3 month). * Participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antioxidant capabilities are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antioxidant capabilities Antioxidant status, inflammation Cardiometabolic health indicators Inflammaging Inflammation biomarkers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad Católica del Maule

    Talca, Maule Region, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.